Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2001 - 2025 of 2088 in total
Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.[A259073, A259078]
Investigational
Cagrilintide is under investigation in clinical trial NCT06221969 (A Research Study to See How Much Cagrisema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor).
Investigational
Experimental
Investigational
Tildacerfont is a corticotropin-releasing factor receptor-1 antagonist containing an unfused thiazole ring
Investigational
This solid compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. This substance targets the protein interleukin-2.
Experimental
Tavokinogene telseplasmid consists of a DNA Plasmid Vector Encoding IL-12.
Investigational
RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A
Investigational
Displaying drugs 2001 - 2025 of 2088 in total